WallStSmart

Cosmos Health Inc. (COSM)vsHenry Schein Inc (HSIC)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Henry Schein Inc generates 18528% more annual revenue ($13.73B vs $73.73M). HSIC leads profitability with a 3.1% profit margin vs -33.1%. HSIC earns a higher WallStSmart Score of 53/100 (C-).

COSM

Hold

36

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 5.0Quality: 4.5
Piotroski: 4/9Altman Z: -2.45

HSIC

Buy

53

out of 100

Grade: C-

Growth: 5.3Profit: 5.5Value: 6.7Quality: 5.0
Piotroski: 2/9Altman Z: 2.37
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for COSM.

HSICUndervalued (+48.0%)

Margin of Safety

+48.0%

Fair Value

$157.15

Current Price

$84.96

$72.19 discount

UndervaluedFair: $157.15Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

COSM1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
28.8%8/10

Revenue surging 28.8% year-over-year

HSIC2 strengths · Avg: 8.0/10
Price/BookValuation
3.0x8/10

Reasonable price relative to book value

EPS GrowthGrowth
26.2%8/10

Earnings expanding 26.2% YoY

Areas to Watch

COSM4 concerns · Avg: 3.3/10
Price/BookValuation
9.6x4/10

Trading at 9.6x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$20.89M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-106.6%2/10

ROE of -106.6% — below average capital efficiency

HSIC4 concerns · Avg: 3.5/10
PEG RatioValuation
1.734/10

Expensive relative to growth rate

Revenue GrowthGrowth
4.0%4/10

4.0% revenue growth

Profit MarginProfitability
3.1%3/10

3.1% margin — thin

Debt/EquityHealth
1.233/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : COSM

The strongest argument for COSM centers on Revenue Growth. Revenue growth of 28.8% demonstrates continued momentum.

Bull Case : HSIC

The strongest argument for HSIC centers on Price/Book, EPS Growth.

Bear Case : COSM

The primary concerns for COSM are Price/Book, EPS Growth, Market Cap.

Bear Case : HSIC

The primary concerns for HSIC are PEG Ratio, Revenue Growth, Profit Margin. Thin 3.1% margins leave little buffer for downturns.

Key Dynamics to Monitor

COSM profiles as a growth stock while HSIC is a value play — different risk/reward profiles.

COSM carries more volatility with a beta of 4.44 — expect wider price swings.

COSM is growing revenue faster at 28.8% — sustainability is the question.

HSIC generates stronger free cash flow (131M), providing more financial flexibility.

Bottom Line

HSIC scores higher overall (53/100 vs 36/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cosmos Health Inc.

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Cosmos Holdings Inc. is a vertically integrated pharmaceutical company. The company is headquartered in Chicago, Illinois.

Henry Schein Inc

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Henry Schein, Inc. is an American distributor of health care products and services with a presence in 32 countries.

Visit Website →

Want to dig deeper into these stocks?